Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-21-enhanced cord blood-derived natural killer cells
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal, Intravenous
01
Overview
Interleukin-21-enhanced cord blood-derived natural killer (NK) cells are an experimental adoptive cell therapy being developed for the treatment of glioblastoma. These cells are derived from umbilical cord blood and genetically modified (transduced) to express Interleukin-21 (IL-21). This modification triggers metabolic reprogramming and enhances mitochondrial fitness, characterized by improved mitochondrial respiration and CEBPD-driven mitophagy. The resulting NK cells exhibit increased diversity, polyfunctionality, and superior anti-tumor potency against glioblastoma stem cells (GSCs), which are typically resistant to conventional therapies. Preclinical studies have demonstrated that these enhanced NK cells can effectively control tumor growth and improve survival in glioblastoma models without significant toxicity.
- Other names
- IL-21-enhanced NK cellsIL21-enhanced NK cellsIL 21-enhanced NK cellsIL-21-transduced cord blood-derived natural killer cellsIL21-transduced cord blood-derived natural killer cellsIL 21-transduced cord blood-derived natural killer cells
02
Targets
CEBPD (CCAAT/enhancer-binding protein delta)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on interleukin-21-enhanced cord blood-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-21-enhanced cord blood-derived natural killer cells.